Key Takeaways

• FDA inspections are increasingly expanding beyond traditional GMP manufacturing operations
• Novo Nordisk reportedly received an FDA Warning Letter tied to adverse event reporting and pharmacovigilance processes
• FDA investigators are placing greater focus on postmarket surveillance systems and enterprise-wide quality oversight
• Pharmacovigilance inspection readiness is becoming critical for biologics, GLP-1s, peptides, and complex drug products
• Companies may face increasing FDA scrutiny involving safety reporting workflows, digital systems, and global quality governance

The FDA’s recent Warning Letter activity involving Novo Nordisk and semaglutide-related pharmacovigilance processes may represent another major signal that FDA inspections are evolving beyond traditional manufacturing floor oversight and into enterprise-wide quality systems evaluation.

As demand for GLP-1 therapies such as Ozempic and Wegovy continues to surge globally, FDA investigators appear to be increasing scrutiny not only of manufacturing operations, but also of postmarket surveillance systems, adverse event reporting processes, and global quality management controls.

According to recent reports, Novo Nordisk disclosed receiving an FDA Warning Letter tied to concerns identified during inspections involving adverse event evaluation and reporting timelines associated with semaglutide products.

FDA Inspections Are Expanding Beyond GMP Manufacturing

Historically, FDA inspections heavily focused on:

• GMP compliance
• aseptic processing
• contamination control
• validation
• laboratory controls
• data integrity
• batch record review
• supplier qualification

However, modern FDA inspections increasingly involve broader evaluation of enterprise-wide quality systems.

FDA investigators may now review:

• pharmacovigilance systems
• adverse event reporting timelines
• complaint handling systems
• signal detection processes
• electronic quality systems
• CAPA effectiveness
• vendor oversight
• digital data management
• global escalation procedures

This represents a significant shift in how companies must approach inspection readiness.

Pharmacovigilance Is Becoming a Major Inspection Focus

As biologics, peptides, GLP-1 therapies, gene therapies, and personalized medicines continue expanding globally, FDA expectations surrounding safety monitoring and postmarket surveillance are likely to intensify.

Postmarket surveillance is no longer viewed as a secondary compliance activity.

It is increasingly treated as a core quality system responsibility.

FDA investigators may evaluate:

• adverse event trending
• medical review procedures
• complaint investigations
• escalation timelines
• signal assessment documentation
• pharmacovigilance vendor oversight
• safety database management
• documentation consistency
• cross-functional communication workflows

Organizations operating internationally may face even greater complexity due to differing global reporting requirements.

Enterprise-Wide Inspection Readiness Is Becoming Essential

For pharmaceutical, biologics, medical device, and combination product manufacturers, inspection readiness can no longer remain siloed within Quality Assurance or Manufacturing departments alone.

Organizations increasingly need alignment across:

• Quality Assurance
• Regulatory Affairs
• Pharmacovigilance
• Manufacturing Operations
• Clinical Operations
• Supply Chain
• Digital Systems
• Executive Leadership

The concept of “quality” is rapidly evolving into enterprise-wide compliance governance.

What This Means for FDA-Regulated Industry

FDA’s evolving inspection approach suggests manufacturers may need stronger:

• cross-functional quality oversight
• integrated reporting systems
• digital governance controls
• adverse event management procedures
• global escalation workflows
• enterprise-wide inspection readiness programs

Companies that proactively strengthen these systems may be better positioned to manage increasing regulatory scrutiny.

Final Thoughts

The Novo Nordisk Warning Letter discussion may become another important example of FDA’s expanding focus on enterprise-wide quality systems and postmarket surveillance oversight.

The future of FDA inspection readiness may depend not only on what occurs inside manufacturing facilities, but also on how effectively organizations manage safety intelligence, digital systems, and lifecycle quality governance across global operations.

Frequently Asked Questions

Why is FDA focusing more on pharmacovigilance during inspections?

FDA is increasingly evaluating how companies monitor product safety after commercialization, including adverse event reporting, signal detection, and complaint investigations.

What is pharmacovigilance?

Pharmacovigilance refers to the processes used to detect, assess, understand, and prevent adverse effects or other drug-related problems after products reach the market.

Are FDA inspections expanding beyond manufacturing?

Yes. FDA inspections increasingly involve enterprise-wide quality systems including digital systems, complaint handling, pharmacovigilance, supplier oversight, and data integrity.

Why are GLP-1 manufacturers receiving increased FDA attention?

The rapid growth of GLP-1 therapies such as Ozempic and Wegovy has increased regulatory focus on manufacturing capacity, safety monitoring, adverse event reporting, and quality system oversight.

What industries could be affected by these evolving FDA inspection trends?

Pharmaceutical, biologics, medical device, cosmetics, dietary supplement, and combination product manufacturers may all face increasing enterprise-wide inspection scrutiny.